B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Clinical trials for B-CELL NON-HODGKIN LYMPHOMA (B-NHL) explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON-HODGKIN LYMPHOMA (B-NHL) trials appear
Sign up with your email to follow new studies for B-CELL NON-HODGKIN LYMPHOMA (B-NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested for tough blood cancers that resist treatment
Disease control OngoingThis is a first-in-human study to find a safe dose and schedule for an experimental drug called PIT565. It is for adults with advanced B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to at least two prior treatments. The main …
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial aims to shrink Tough-to-Treat lymphomas
Disease control OngoingThis study is testing an experimental drug called odronextamab in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are to see how well the drug shrinks tumors and to understand its safety. Researchers are …
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC